Phase 3 Readout~month

Phase 3 Topline: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology

Indication
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Other upcoming events for COSM

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient
Phase 3 ReadoutPhase 3 Topline: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Pat
Patent ExpiryPatent/Exclusivity Expiry: VYXEOS
Patent ExpiryPatent/Exclusivity Expiry: KHAPZORY
Patent ExpiryPatent/Exclusivity Expiry: IMKELDI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology — COSM Phase 3 Readout | BioSniper